胃癌治療國(guó)際高峰論壇 更多 >>
- 胃癌藥物臨床試驗(yàn)對(duì)比--愛(ài)斯萬(wàn)?的優(yōu)勢(shì)
- S-1治療中國(guó)晚期胃癌患者的多中心臨床研究報(bào)告（SC-101）
- 有愛(ài)有未來(lái)-愛(ài)斯萬(wàn)?中國(guó)上市會(huì)紀(jì)實(shí)
- 胃癌治療國(guó)際高峰論壇 會(huì)議通知
- 東西方胃癌治療的差異
- 會(huì)議專(zhuān)家簡(jiǎn)介：管忠震教授
- S-1單藥對(duì)比S-1/CDDP聯(lián)合對(duì)比5-FU/CDDP聯(lián)合治療 ...
- StageII/III胃癌根治術(shù)后S-1單藥輔助化療對(duì)比單純手術(shù)治療的III期隨機(jī)臨床試驗(yàn)
Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR stud
發(fā)布日期：2009-09-29 17:23 文章來(lái)源：丁香園
分享到： 收藏夾 新浪微博 騰訊微博 開(kāi)心網(wǎng) 豆瓣社區(qū) 人人網(wǎng)
點(diǎn)擊次數(shù)：
V. C. Tjan-Heijnen, M. J. Pepels, M. de Boer, G. F. Borm, J. A. van Dijck, C. H. van Deurzen, E. M. Adang, M. B. Menke-Pluymers, P. J. van Diest, P. Bult
Background: The Dutch MIRROR study is the largest cohort study on pN1mi and pN0(i+) in the SN era with long-term follow-up, central pathology review (6th AJCC-classification), and separate analyses on the use of adjuvant systemic therapy (AST). In patients not receiving AST, pN1mi and pN0(i+) as final N-stage were shown to be independent prognosticators for disease-free survival (SABCS 2008, #23, oral). As a substantial number of patients in the MIRROR study did not undergo cALND or ax RT, we questioned whether this policy was safe in patients with pN1mi(sn) or pN0(i+)(sn).
Methods: Patients operated for breast cancer in all Dutch hospitals in the years 1998-2005, having favorable primary tumor characteristics, and having undergone an SN biopsy without macrometastases as final N-stage were included. For this present research question, patients were categorized by their SN-stage. Median follow-up was 4.7 years. The Kaplan-Meier method was used to estimate 5-year axillary recurrence (AR) rates, and Cox regression was used to estimate the hazard ratios (HR). In the analyses, the effect of AST was taken into account.
Results: In total, 835 patients with pN0(i-)(sn), 799 patients with pN0(i+)(sn), and 958 patients with pN1mi(sn) were included. AR rates, and HRs on AR are displayed below.
Conclusions: Omission of cALND or ax RT in patients with pN1mi(sn) resulted in a significantly higher 5-year AR rate, even after correction for AST, and other patient and tumor characteristics. This indicates that patients with pN1mi(sn) should undergo cALND or ax RT to prevent AR. Support: The Netherlands Organization for Health Research and Development (ZonMw) and the Dutch Breast Cancer Trialists' Group (BOOG).
編輯: ludongcn 作者:丁香園通訊員
以下網(wǎng)友留言只代表網(wǎng)友個(gè)人觀點(diǎn)，不代表網(wǎng)站觀點(diǎn)
